Pharmaceutical patent analyst · 2025
Trivalent bispecific anti-MSLN2/CD3 antibody for cancer treatment.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saldaña Jorge Antonio Perez, Flores-Robles Donaciano, Montes Antonio Celestino, Millán-Vega Alejandro, Sierra-Martínez Pavel, Perez-Santos Martin
Аннотация
INTRODUCTION: Mesothelin protein is an overexpressed molecule in epithelioid mesothelioma, epithelial ovarian cancer, and pancreatic adenocarcinoma, which is why it is considered a potential therapeutic target.
AREAS COVERED: WO2024082060 patent describes a trivalent bispecific antibody directed against MSLN/CD3/MSLN, and lung cancer treatment method. This antibody exhibits binding activity to MSLN-containing tumor cells, as well as inhibition of tumor growth rate in murine models of lung and ovarian cancer.
EXPERT OPINION: The trispecific structure suggesting that this antibody is a potential candidate for clinical trials for the treatment of lung cancer associated with high levels of MSLN expression.
AREAS COVERED: WO2024082060 patent describes a trivalent bispecific antibody directed against MSLN/CD3/MSLN, and lung cancer treatment method. This antibody exhibits binding activity to MSLN-containing tumor cells, as well as inhibition of tumor growth rate in murine models of lung and ovarian cancer.
EXPERT OPINION: The trispecific structure suggesting that this antibody is a potential candidate for clinical trials for the treatment of lung cancer associated with high levels of MSLN expression.